Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tropifexor ± Licogliflozin in NASH with Fibrosis (China subset of global phase 2)
CTR20202498Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tropifexor, licogliflozin in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Novartis. Started Dec 2020; status: terminated.
02
Drugs
tropifexorlicogliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20202498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202498.